


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

In re Application of

Application Number

08/373,857

Filed

11/18/95

Group Art Unit

Examiner

Paper No. 15Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

☒ (A) referred to in United States Patent Number 5,932,214, column 63.☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____.☐ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or☐ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Joshua Woods

Signature

JOSHUA WOODS

Typed or printed name

7/7/00

Date

RECEIVED

FOR PTO USE ONLY

Approved by: JUL 07 2000

(initials)

File Information Unit

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



US005932214A

United States Patent [19]

Lobb et al.

[11] Patent Number: 5,932,214

[45] Date of Patent: Aug. 3, 1999

[54] TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH VLA-4 BLOCKERS

[75] Inventors: Roy R. Lobb, Westwood; Linda C. Burkly, West Newton, both of Mass.

[73] Assignee: Biogen, Inc., Cambridge, Mass.

[21] Appl. No.: 08/950,660

[22] Filed: Oct. 15, 1997

Related U.S. Application Data

[62] continuation of application No. 08/456,124, May 31, 1995., abandoned, which is a continuation-in-part of application No. 08/373,857, Jan. 18, 1995., abandoned, which is a continuation-in-part of application No. 08/284,603, Aug. 11, 1994., abandoned, which is a continuation-in-part of application No. 07/835,139, filed as application No. PCT/US93/00924, Feb. 2, 1993., abandoned

[51] Int. Cl.⁶ A61K 39/395; A61K 38/17

[52] U.S. Cl. 424/144.1; 424/130.1;
424/133.1; 424/134.1; 424/136.1; 424/141.1;
424/143.4; 424/153.1; 424/154.1; 514/2;
514/8; 514/885; 530/350; 530/387.1; 530/387.3;
530/388.1; 530/388.2; 530/388.22; 530/388.7;
530/388.73; 530/388.75

[58] Field of Search 424/130.1, 133.1,
424/141.1, 153.1; 514/2, 8; 530/350, 388.1,
388.7

[56] References Cited

U.S. PATENT DOCUMENTS

4,816,397 3/1989 Boss et al. 435/68
4,833,092 5/1989 Geysen 436/501
5,116,964 5/1992 Capon et al. .
5,272,263 12/1993 Hession et al. .
5,730,978 3/1998 Wayner .

FOREIGN PATENT DOCUMENTS

0 314 863 5/1989 European Pat. Off. .
0 330 506 9/1989 European Pat. Off. .
0 333 517 9/1989 European Pat. Off. .
0 346 078 12/1989 European Pat. Off. .
WO 90/03400 4/1990 WIPO .
WO 90/13300 11/1990 WIPO .
9103252 3/1991 WIPO .
WO 92/00751 1/1992 WIPO .
WO 93/13798 1/1992 WIPO .
WO 95/19790 7/1995 WIPO .

OTHER PUBLICATIONS

Jakubowski, et al. "Vascular Cell Adhesion Molecule (VCAM)-Ig Fusion Protein Defines Distinct Affinity States of the Very Late Antigen-4 (VLA-4) Receptor" *Cell Adhesion and Communication* 3:131-142 (1995).

Brown, Jr., P. et al., "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor, Prolongs Primate Cardiac Allograft Survival" *Proc. Natl. Acad. Sci. USA* 88:2663-2667 (1990).

Burkly, L. et al., "Signaling by Vascular Cell Adhesion Molecule-1 (VCAM-1) Through VLA-4 Promotes CD3-dependent T Cell Proliferation" *Eur. J. Immunol.* 21:2871-2875 (1991).

Clackson, T. et al., "Making Antibody Fragments Using Phage Display Libraries" *Nature* 352:624-628 (1991).

Co, M.S. et al., "Humanized Antibodies for Antiviral Therapy" *Proc. Natl. Acad. Sci. USA* 88:2869-2873 (1990).

Damle, N. et al., "Vascular Cell Adhesion Molecule 1 Induces T-cell Antigen Receptor-dependent Activation of CD4⁺ T Lymphocytes" *Proc. Natl. Acad. Sci. USA* 88:6403-6407 (1991).

Devlin, J. et al., "Random Peptide Libraries: A Source of Specific Protein Binding Molecules" *Science* 249:400-406 (1990).

Dobrina, A. et al., "Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells" *J. Clin. Invest.* 88:20-26 (1991).

Elices, M.J. et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site" *Cell* 60:577-584 (1990).

Freedman, A. et al., "Adhesion of Human B Cells to Germinal Centers in Vitro Involves VLA-4 and INCAM-110" *Science* 249:1030-1033 (1990).

Harris, W.J. and S. Emery, "Therapeutic antibodies—the coming of age" *TIBTECH* 11: 42-44 (1993).

Hemler, M. E. et al., "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides" *J. Biol. Chem.* 262(24):11478-11485 (1987).

Holzmann, B. and I.L. Weissman, "Integrin Molecules Involved in Lymphocyte Homing to Peyer's Patches" *Immunological Reviews* 0(108):45-61 (1989).

Podolsky, D.K. et al., "Colonic Mucin Composition in Primates Selective Alterations Associated with Spontaneous Colitis in the Cotton-top Tamarin" *Gastroent.* 88:20-25 (1985).

Podolsky, D.K. et al., "Spontaneous Colitis In Cotton-Top Tamarins: Histologic, Clinical and Biochemical Features of an Animal Model of Chronic Colitis" *Digestive Diseases and Sciences* 30(4):396 (A-32) (1985).

Pulido, R. et al., "Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4" *J. Biol. Chem.* 266(16):10241-10245 (1991).

Rice, G.E. et al., "Vascular and Nonvascular Expression of INCAM-110", *Am. J. Pathology* 138(2):385-393 (1991).

Riechmann, L. et al., "Reshaping Human Antibodies for Therapy" *Nature* 332:323-327 (1988).

(List continued on next page.)

Primary Examiner—Christina Y. Chan

Assistant Examiner—Phillip Gambel

Attorney, Agent, or Firm—Fish & Richardson P.C.

[57]

ABSTRACT

A method for the treatment of inflammatory bowel disease (IBD) is disclosed. The method comprises administration of an antibody, polypeptide or other molecule recognizing VLA-4, a surface molecule expressed on most types of white blood cells and involved in leukocyte adhesion to endothelium and other tissue in the gut.

15 Claims, 8 Drawing Sheets